Scalper1 News
Biotech Intercept Pharmaceuticals (ICPT) spiked more than 9% to near 285 Thursday afternoon when a competitor’s clinical trial produced ambiguous results. GenFit, a French biotech that doesn’t trade in the U.S., announced that its drug GFT505 had failed to meet its primary endpoint in non-alcoholic steatohepatitis (NASH), a form of liver damage caused by accumulation of fat. Progress was measured by performing a liver biopsy at the beginning and Scalper1 News
Scalper1 News